MAY 15, 2022 11:00 AM PDT

Implanted Insulin-producing Cells for Diabetes Treatment

WRITTEN BY: Ryan Vingum

Type 1 diabetes, which affects about 9 to 10 million people globally, occurs when the immune system incorrectly identifies cells that produce insulin in the pancreas as “foreign,” and destroys them. Usually, the body has tools in place to calm an immune system after neutralizing a threat. However, these tools sometimes fail. As a result, the immune system continues to attack insulin-producing cells, which means the body is not making enough insulin to manage glucose levels in the body.

Management of this condition requires careful adherence to certain diet restrictions and administration of insulin, when needed. For many people, though, diabetes can lead to serious complications, including damage to the heart and kidney.

Researchers at the University of Missouri-Columbia have developed a new treatment for type 1 diabetes, and it has proven successful in animal models. The new treatment and results from the animal models are described in a study published in Science Advances

Specifically, the treatment involves the transplantation of islets, or cells that produce insulin. However, unlike other transplantation efforts, there is no need for long-term use of immunosuppressants. 

A big challenge to this kind of transplantation has to do with the body’s incorrect response to insulin-producing cells.. The body’s normal process for shutting down certain immune system cells, a process called apoptosis, or programmed cell death, usually doesn’t work in people with diabetes.

The research team is using the mechanism behind apoptosis to help transplanted insulin-producing cells survive. Specifically, the team is mimicking the interaction between two molecules: FasL, which appear on insulin-producing cells, and Fas, which occur on immune cells. The transplanted insulin-producing cells have an engineered form of FasL on them to prevent the immune system from destroying them.  

A potential benefit of this approach is that it reduces the need for immunosuppressive treatment. Normally, this treatment would be needed to override the immune system and prevent it from destroying these new insulin-producing cells, but this comes with a range of risks and complications. Allowing the cells to exist without messing with the immune system could lead to better outcomes for patients. 

Sources: EurekaAlert!; Science Advances; WHO

About the Author
Professional Writing
Science writer and editor, with a focus on simplifying complex information about health, medicine, technology, and clinical drug development for a general audience.
You May Also Like
APR 28, 2022
Genetics & Genomics
A Genetic Cause of Lupus is Identified
APR 28, 2022
A Genetic Cause of Lupus is Identified
Lupus is an autoimmune disease that can impact anyone, but tends to affects women between the ages of 15 and 45. The dis ...
MAY 07, 2022
Drug Discovery & Development
Ibuprofen and Blood Pressure Medication Linked to Kidney Damage
MAY 07, 2022
Ibuprofen and Blood Pressure Medication Linked to Kidney Damage
A combination of ibuprofen and certain blood pressure medications could lead to acute kidney injury. The corresponding s ...
MAY 13, 2022
Drug Discovery & Development
Promising New Treatment for Cat Litter Parasite T. Gondii
MAY 13, 2022
Promising New Treatment for Cat Litter Parasite T. Gondii
Researchers have discovered a promising therapy for those suffering from toxoplasmosis, a disease caused by a parasite l ...
JUN 02, 2022
Drug Discovery & Development
NSAIDs Can Have Different, Unexpected Effects on People. Why?
JUN 02, 2022
NSAIDs Can Have Different, Unexpected Effects on People. Why?
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most common types of drugs used to treat pain and inflammat ...
JUN 21, 2022
Cell & Molecular Biology
From sample collection straight to RT-qPCR
JUN 21, 2022
From sample collection straight to RT-qPCR
Skip the nucleic acid purification step in your cancer detection workflow. Learn more about how Thermo Fisher Scientific ...
JUN 19, 2022
Drug Discovery & Development
Oral Immunotherapy for Peanut Allergy Most Effective Before 12 Months Old
JUN 19, 2022
Oral Immunotherapy for Peanut Allergy Most Effective Before 12 Months Old
Oral immunotherapy for peanut allergies is safer and more effective in children under 12 months old than in toddlers and ...
Loading Comments...